HAE at a glance
HAEMONETICS CORP (HAE, SEC CIK 313143) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding HAEMONETICS CORP (HAE) shares worth $2.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Maunsell Farris Maryanne on November 11, 2026 of 836 shares at $120.99 per share.
- In the last 90 days, HAE insiders reported 0 open-market purchases ($0) and 1 open-market sale ($101K) on Form 4, a net sale of $101K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.3B
- −2.0% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$101K
- 13F holders
- 34 funds
- $2.5B · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material changes from the fiscal 2026 Form 10-K risk factors
- Carried-forward risks remain unchanged, with no new triggers identified
Management Discussion & Analysis
- Revenue $357.8M, up 9.3% YoY from $327.3M
- Operating margin 21.0% vs 17.9% YoY, net margin 12.9% vs 11.8%
- Best performer: Plasma revenue $162.6M, up 16.5%; worst: Interventional Technologies $60.5M, up 2.4%
- Cash $260.7M vs $245.4M; operating cash flow $180.4M vs $128.7M for six months
- $100.0M revolving-credit repayment; CSL rollout expected by end of calendar year 2027, timing subject to change
AI summary of the HAE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Haemonetics announced fiscal 2027 second-quarter and first-half financial results
- Results cover the quarter ended September 26, 2026
Item EX-99.1: Item EX-99.1
- Q2 FY27 revenue $357.8M, up 9.3%, with organic growth 10.0%, signaling broad operating momentum
- Apheresis led growth at 12.6% reported and 13.6% organic, while MedSurg delivered 5.1% reported growth
Item 7.01: Regulation FD Disclosure
- CSL expects rollout of Haemonetics’ NexSys PCS devices and Persona PLUS disposables across all current U.S. plasma centers by end-2027
- Potentially broad customer conversion expands Haemonetics’ recurring disposable-product opportunity with a major plasma collector
Item 7.01: Regulation FD Disclosure
- Supply agreement with CSL Plasma for NexSys PCS devices, Persona PLUS technology and related U.S. disposables
- Non-exclusive arrangement with no minimum purchase commitments, limiting near-term revenue certainty
AI summaries of HAE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HAE
Don't miss the next HAE filing
- Alerts as it files. A push when HAE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HAE, by share count.
- Ask anything. An AI agent that reads every HAE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 1,068 | - |
| Maunsell Farris Maryanne | F | Nov 11, 2026 | 1,724 | $121.10 |
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 433 | $70.31 |
| Maunsell Farris Maryanne | Sell | Nov 11, 2026 | 836 | $120.99 |
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 433 | - |
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 645 | - |
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 1,068 | $89.16 |
| Maunsell Farris Maryanne | M | Nov 11, 2026 | 645 | $95.73 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.4B | $1.3B |
| Gross Profit | - | $749.0M | $787.6M |
| Operating Income | - | $221.8M | $156.7M |
| Net Income | - | $167.7M | $97.3M |
| Gross Margin | - | 55.0% | 59.0% |
| Op. Margin | - | 16.3% | 11.7% |
| Net Margin | - | 12.3% | 7.3% |
| Balance Sheet | |||
| Total Assets | $2.2B | $2.5B | $2.4B |
| Equity | - | $820.8M | $796.3M |
| ROE | - | 20.4% | 12.2% |
| Per Share | |||
| EPS | - | $3.31 | $2.05 |
| Cash Flow | |||
| Operating CF | - | $181.7M | $293.2M |
| CapEx | $66.3M | $39.3M | $32.8M |
Source: XBRL data in HAEMONETICS CORP (HAE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HAE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $2.51B |
| Q2 2026 | 35 | $1.79B |
| Q1 2026 | 36 | $1.31B |
| Q4 2025 | 29 | $1.99B |
| Q3 2025 | 29 | $1.14B |
| Q2 2025 | 29 | $1.57B |
| Q1 2025 | 26 | $877.8M |
| Q4 2024 | 23 | $925.1M |
- T. Rowe Price Group+422.4K (+66%)
- Goldman Sachs Group+322.2K (+31%)
- Citadel Advisors LLC+152.7K (+10%)
- Millennium Management+66.5K (+12%)
- Franklin Resources+55.7K (+16%)
- AQR Capital Management−443.9K (-20%)
- Dimensional Fund Advisors−305.5K (-19%)
- Morgan Stanley−69.5K (-15%)
- Citigroup−67.2K (-21%)
- Vanguard Portfolio Management LLC−45.2K (-2%)
- FMR LLC (Fidelity)−288.1K
- Two Sigma Investments−10.6K
- Blackstone Group−8.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HAE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 26, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 27, 2026 | Analysis | |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 10-K | May 20, 2026 | Mar 28, 2026 | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
HAE SEC filings: frequently asked questions
Are HAE insiders buying or selling?
In the last 90 days, HAEMONETICS CORP (HAE) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $101,148 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold HAE stock?
As of September 30, 2026, the largest HAEMONETICS CORP (HAE) holders among the 13F filers tracked by SignalX were BlackRock ($626.9 million), Vanguard Portfolio Management LLC ($263.4 million), Vanguard Capital Management LLC ($215.4 million), AQR Capital Management ($189.5 million), State Street Corp ($189.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HAE's revenue in fiscal year 2026?
For the fiscal year ended March 28, 2026 (FY2026), HAEMONETICS CORP (HAE) reported revenue of $1.3 billion (down 2.0% from FY2025) and net income of $97.3 million. Diluted EPS was $2.05. The figures come from the XBRL data in the 10-K.
What did HAE report in its latest 8-K?
HAEMONETICS CORP (HAE) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Haemonetics announced fiscal 2027 second-quarter and first-half financial results.
What are the latest HAE SEC filings?
HAEMONETICS CORP (HAE) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.
What is HAE's SEC CIK number?
HAEMONETICS CORP (HAE)'s SEC Central Index Key (CIK) is 313143. EDGAR lists every HAE filing under that number.
Ask anything about HAE
The research agent reads HAE's filings, financials, insider trades and 13F holders, then answers with sources.